SA
KRYS icon

Sanctuary Advisors’s Krystal Biotech KRYS Stock Holding History

Sanctuary Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1M Sell
2,692
-3,338
-55% -$997K ﹤0.01% 1445
2026
Q1 		$1.56M Buy
+6,030
New +$1.6M 0.01% 1082

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sanctuary Advisors's KRYS Position: Q2 2026 in Review

Sanctuary Advisors reduced its Krystal Biotech (KRYS) stake by 55% in Q2 2026, selling an estimated $997K and leaving 2,692 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #1445.

Sanctuary Advisors first reported a position in KRYS in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.56M in Q1 2026. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Sanctuary Advisors held 2,692 shares of Krystal Biotech worth $1M as of Q2 2026.
  • Sanctuary Advisors sold 3,338 Krystal Biotech shares in Q2 2026, an estimated $997K.
  • Krystal Biotech made up ﹤0.01% of Sanctuary Advisors's portfolio in Q2 2026, its #1445 holding.
  • Sanctuary Advisors first reported a position in Krystal Biotech in Q1 2026 and has held it in 2 quarters since.
  • Sanctuary Advisors's Krystal Biotech position peaked at $1.56M in Q1 2026.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.